Trending NewsTrending NewsNYSE:NVO Novo Nordisk A/S (NVO) Stock Price, News & Analysis $41.13 +0.43 (+1.06%) Closing price 03:59 PM EasternExtended Trading$40.85 -0.28 (-0.69%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Novo Nordisk A/S Stock (NYSE:NVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novo Nordisk A/S alerts:Sign Up Key Stats Today's Range$40.10▼$41.2050-Day Range$37.31▼$47.4552-Week Range$35.12▼$64.16Volume11.68 million shsAverage Volume11.19 million shsMarket Capitalization$183.65 billionP/E Ratio10.36Dividend Yield1.97%Price Target$59.44Consensus RatingHold Company Overview Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989. The company is headquartered in Bagsværd, Denmark.AI Generated. May Contain Errors. Read More Novo Nordisk A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreNVO MarketRank™: 4.03001704024 of 5 starsNovo Nordisk A/S scored higher than 81% of companies evaluated by MarketBeat, and ranked 85th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingNovo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 5 buy ratings, 16 hold ratings, and 5 sell ratings.Upside PotentialNovo Nordisk A/S has a consensus price target of $59.44, representing about 44.5% upside from its current price of $41.13.Amount of Analyst CoverageNovo Nordisk A/S has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novo Nordisk A/S's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth2.07% Earnings GrowthEarnings for Novo Nordisk A/S are expected to grow by 2.07% in the coming year, from $3.38 to $3.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novo Nordisk A/S is 10.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Novo Nordisk A/S is 10.36, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.15.Price to Earnings Growth RatioNovo Nordisk A/S has a PEG Ratio of 1.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovo Nordisk A/S has a P/B Ratio of 5.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.86% of the float of Novo Nordisk A/S has been sold short.Short Interest Ratio / Days to CoverNovo Nordisk A/S has a short interest ratio ("days to cover") of 4.04.Change versus previous monthShort interest in Novo Nordisk A/S has recently increased by 2.27%, indicating that investor sentiment is decreasing. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovo Nordisk A/S pays a meaningful dividend of 1.97%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovo Nordisk A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novo Nordisk A/S is 20.40%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 23.48% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.Read more about Novo Nordisk A/S's dividend. News and Social Media2.8 / 5News Sentiment0.53 News SentimentNovo Nordisk A/S has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Novo Nordisk A/S this week, compared to 7 articles on an average week.Search InterestOnly 52 people have searched for NVO on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows35 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 192% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.Percentage Held by Insiders0.07% of the stock of Novo Nordisk A/S is held by insiders.Percentage Held by Institutions11.54% of the stock of Novo Nordisk A/S is held by institutions.Read more about Novo Nordisk A/S's insider trading history. Receive NVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVO Stock News HeadlinesNovo Nordisk: Valuations Are Blind To The Upside2 minutes ago | seekingalpha.comJPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?3 hours ago | fool.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 11 at 1:00 AM | Paradigm Press (Ad)Novo Nordisk A/S: Novo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and careNovember 11 at 9:33 AM | finanznachrichten.deNovo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and careNovember 11 at 9:33 AM | finance.yahoo.comHims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds SteadyNovember 10 at 1:52 PM | 247wallst.comBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts (NVO)MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.October 26, 2026 | marketbeat.comOnly 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI (NVO)Stansberry Research's Whitney Tilson argues record highs mask a bifurcated market, favoring Joby Aviation, Casey's General Stores, and Eli Lilly as value picks outside the AI trade.October 15, 2026 | marketbeat.comSee More Headlines NVO Stock Analysis - Frequently Asked Questions How have NVO shares performed this year? Novo Nordisk A/S's stock was trading at $50.88 on January 1st, 2026. Since then, NVO shares have decreased by 19.2% and is now trading at $41.13. How were Novo Nordisk A/S's earnings last quarter? Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings data on Wednesday, August, 5th. The company reported $0.96 earnings per share for the quarter, beating analysts' consensus estimates of $0.77 by $0.19. The firm had revenue of $11.98 billion for the quarter, compared to the consensus estimate of $10.89 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 53.52% and a net margin of 33.99%. Read the conference call transcript. When did Novo Nordisk A/S's stock split? Shares of Novo Nordisk A/S split on the morning of Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly minted shares were issued to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Novo Nordisk A/S have any subsidiaries? Novo Nordisk A/S subsidiaries include Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and more. Who are Novo Nordisk A/S's major shareholders? Top institutional investors of Novo Nordisk A/S include Fisher Asset Management LLC (0.18%), Everett Harris & Co. CA (0.14%), Cullen Capital Management LLC (0.02%) and Boston Partners (0.01%). View institutional ownership trends. How do I buy shares of Novo Nordisk A/S? Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novo Nordisk A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Eli Lilly and Company (LLY), Tesla (TSLA), Broadcom (AVGO), Palantir Technologies (PLTR) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings8/05/2026Record date for 8/25 Dividend8/17/2026Ex-Dividend for 8/25 Dividend8/17/2026Dividend Payable8/25/2026Today11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 6 days, NVO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NVO CIK353278 Webwww.novonordisk.com Phone(454) 444-8888Fax45-4449-0555Employees69,505Year Founded1923Price Target and Rating Average Price Target for Novo Nordisk A/S$59.44 High Price Target$175.00 Low Price Target$38.00 Potential Upside/Downside+44.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$3.97 Trailing P/E Ratio10.36 Forward P/E Ratio11.92 P/E Growth1.4Net Income$15.51 billion Net Margins33.99% Pretax Margin43.58% Return on Equity53.52% Return on Assets19.49% Debt Debt-to-Equity Ratio0.54 Current Ratio0.84 Quick Ratio0.64 Sales & Book Value Annual Sales$333.65 billion Price / Sales0.55 Cash Flow$4.74 per share Price / Cash Flow8.68 Book Value$7.51 per share Price / Book5.48Miscellaneous Outstanding Shares4,465,000,000Free Float4,461,875,000Market Cap$183.65 billion OptionableOptionable Beta0.70 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSE:NVO) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Nordisk A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novo Nordisk A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVO Stock Alerts